Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2014 1
2015 1
2016 1
2018 1
2020 1
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
Liu Z, Alexander JL, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin KW, McFarlane LR, Constable L, Seoane RC, Anand N, Bewshea C, Nice R, D'Mello A, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HR, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Hart AL, Lees CW, Goodhand JR, Kennedy NA, Pollock KM, Ahmad T, Powell N; VIP study investigators. Liu Z, et al. Among authors: anand n. EClinicalMedicine. 2023 Oct 5;64:102249. doi: 10.1016/j.eclinm.2023.102249. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37842172 Free PMC article.
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Goodhand JR, Hart AL, Lees CW, Boyton RJ, Kennedy NA, Ahmad T, Powell N; VIP study investigators. Alexander JL, et al. Among authors: anand n. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9. Lancet Gastroenterol Hepatol. 2022. PMID: 36088954 Free PMC article.
Audioprofile Surfaces: The 21st Century Audiogram.
Taylor KR, Booth KT, Azaiez H, Sloan CM, Kolbe DL, Glanz EN, Shearer AE, DeLuca AP, Anand VN, Hildebrand MS, Simpson AC, Eppsteiner RW, Scheetz TE, Braun TA, Huygen PL, Smith RJ, Casavant TL. Taylor KR, et al. Among authors: anand vn. Ann Otol Rhinol Laryngol. 2016 May;125(5):361-8. doi: 10.1177/0003489415614863. Epub 2015 Nov 3. Ann Otol Rhinol Laryngol. 2016. PMID: 26530094 Free PMC article.
Pericentral hydroxychloroquine retinopathy in a Caucasian female.
Anand N, Prinzi RA, Hoeferlin C, Yan J, Jain N. Anand N, et al. Am J Ophthalmol Case Rep. 2018 Jan 13;9:93-95. doi: 10.1016/j.ajoc.2018.01.019. eCollection 2018 Mar. Am J Ophthalmol Case Rep. 2018. PMID: 29577098 Free PMC article.
Exon-level expression profiling of ocular tissues.
Wagner AH, Anand VN, Wang WH, Chatterton JE, Sun D, Shepard AR, Jacobson N, Pang IH, Deluca AP, Casavant TL, Scheetz TE, Mullins RF, Braun TA, Clark AF. Wagner AH, et al. Among authors: anand vn. Exp Eye Res. 2013 Jun;111:105-11. doi: 10.1016/j.exer.2013.03.004. Epub 2013 Mar 14. Exp Eye Res. 2013. PMID: 23500522 Free PMC article.
Cordova: web-based management of genetic variation data.
Ephraim SS, Anand N, DeLuca AP, Taylor KR, Kolbe DL, Simpson AC, Azaiez H, Sloan CM, Shearer AE, Hallier AR, Casavant TL, Scheetz TE, Smith RJ, Braun TA. Ephraim SS, et al. Among authors: anand n. Bioinformatics. 2014 Dec 1;30(23):3438-9. doi: 10.1093/bioinformatics/btu539. Epub 2014 Aug 14. Bioinformatics. 2014. PMID: 25123904 Free PMC article.
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z, Alexander JL, Lin KW; VIP Study Investigators; Ahmad T, Pollock KM, Powell N. Liu Z, et al. Gastroenterology. 2023 Feb;164(2):300-303.e3. doi: 10.1053/j.gastro.2022.10.010. Epub 2022 Oct 19. Gastroenterology. 2023. PMID: 36270334 Free PMC article. No abstract available.
14 results